Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...

Two of the most recommended meds nowadays that may aid in reducing weight are Mounjaro and Ozempic ... dosage as much as 2.5 mg every 4 weeks up to a maximum dose of 15 mg once a week.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

It is the largest study ever of the drug category—which includes Novo Nordisk’s GLP-1 treatments Ozempic and Wegovy and Eli Lilly’s dual-action GLP-1/GIP agonists Mounjaro and Zepbound.

While much attention focuses on Lilly's incretin franchise, Mounjaro and Zepbound ... the company has launched a single-dose 2.5 mg and 5 mg Zepbound vials in the U.S. exclusively through ...

Shares of Eli Lilly & Co. were headed for their worst day in nearly four years on Tuesday after the drugmaker provided a fourth-quarter revenue outlook that was below expectations, citing slower ...

Shares of Eli Lilly were taking ... and obesity drugs, Mounjaro and Zepbound. The stock was headed for its biggest one-day drop since the 9.1% selloff on March 15, 2021. Despite the stock's ...

I think what really caused the recent sell-off was Lilly's specific guidance related to its blockbuster GLP-1 drugs, Mounjaro and Zepbound. For the fourth quarter, Lilly calls for revenue of $3.5 ...

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December scripts boost. The stock is attractively valued at current levels.

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.